The researchers focused on four biomarkers that clinicians already measure in everyday practice. Glycated hemoglobin, or HbA1c, reflects average blood glucose over roughly two to three months and is the standard yardstick of long-term diabetic control. Fasting plasma glucose, or FPG, captures the sugar level at a single point in time after an overnight fast. The triglyceride-glucose index, known as the TyG index, is a calculated value derived from fasting triglycerides and glucose that serves as a convenient proxy for insulin resistance. Adiponectin, by contrast, is a hormone secreted by fat tissue that generally improves insulin sensitivity, so higher levels might be expected to protect rather than harm the brain.

To be included in the analysis, studies had to enroll older adults with diabetes who were free of cognitive impairment or dementia at baseline, then follow them over time or assess cognition at a single point. The team searched PubMed, Embase, the Cochrane Library, and Web of Science for literature published between 2000 and March 13, 2026. They pooled effect sizes using random-effects models, which assume that the true association may vary from study to study, and for fasting glucose they went a step further, applying restricted cubic splines to model a non-linear dose-response relationship between glucose levels and dementia risk.

The headline finding concerns HbA1c. Across 24 studies reporting cognitive impairment, involving 8,473 participants, elevated HbA1c was associated with a 22 percent increase in the odds of cognitive impairment, with an odds ratio of 1.22. For dementia, drawn from 6 studies and 4,677 participants, the association was stronger: an odds ratio of 1.60, meaning roughly a 60 percent increase in odds. These are modest but clinically meaningful effect sizes, and they align with the broader hypothesis that chronic hyperglycemia damages cerebral vasculature and neurons through mechanisms including oxidative stress, inflammation, and impaired clearance of amyloid proteins.

However, the authors themselves urge caution on the HbA1c result. Funnel plot asymmetry, a significant Egger’s test with a t-statistic of 5.38 and a P value below 0.01, and a trim-and-fill analysis imputing 13 missing studies all pointed to substantial publication bias, the tendency for studies finding strong associations to be published more readily than null results. When such bias is present, pooled estimates can be inflated, so the true association between HbA1c and cognitive decline may be weaker than the headline numbers suggest. The research team explicitly states that the pooled estimate should be interpreted with caution.

Fasting glucose told a more nuanced story. Across 6 studies of dementia with 3,177 participants, higher FPG was associated with a 36 percent increase in dementia odds. But the dose-response analysis revealed something more interesting: the relationship was non-linear, with a P value for non-linearity of 0.008 and an overall P value below 0.001. At moderate glucose elevations the risk rose gently, but above roughly 10.5 millimoles per liter the curve steepened sharply, with the relative risk reaching 1.51 at that threshold and 1.77 at 12.5 millimoles per liter. This pattern suggests there may be a tipping point beyond which each additional increment of fasting glucose carries disproportionately greater danger for the aging brain. The caveat, however, is stark: the dose-response analysis rested on only 3 studies, a very limited sample size.

The TyG index and adiponectin results are even more preliminary. A single study with 308 participants linked higher TyG index values to cognitive impairment, with an odds ratio of 2.24, the largest effect size in the review, and another study with 739 participants examined dementia. Adiponectin, measured in just 2 studies with 251 participants, emerged as a protective factor, associated with a 33 percent reduction in the odds of cognitive impairment. The authors are careful to frame both findings as exploratory and hypothesis-generating rather than confirmatory, and no study in the pool examined adiponectin in relation to dementia at all.

Heterogeneity, the statistical term for variability among studies, was substantial across the analyses, with I-squared values ranging from 58.7 to 69.5 percent and P values below 0.05. In practical terms, this means the individual studies differed considerably in their populations, biomarker cutoffs, cognitive assessment methods, and follow-up durations, which limits confidence that any single pooled number captures a universal truth. Random-effects models partially accommodate this variability, but they cannot eliminate the underlying diversity in how the studies were conducted.

Why does any of this matter? Diabetes affects hundreds of millions of people worldwide, and older adults with the condition already face elevated dementia risk compared with their non-diabetic peers. If simple, inexpensive blood tests could flag which patients are drifting toward cognitive decline, clinicians could intensify monitoring, optimize glucose management, and potentially intervene earlier with lifestyle and pharmacological strategies. The TyG index is particularly attractive from a screening standpoint because it requires only two values from a standard metabolic panel, making it nearly free to calculate in any clinic.

The review’s authors conclude that elevated HbA1c, fasting glucose, and TyG index levels were associated with increased risk of cognitive impairment and dementia in elderly diabetic patients, with modest effect sizes overall, while adiponectin showed a possible protective signal. They call for more high-quality cohort investigations to explore the long-term associations, particularly given the thin evidence base behind the TyG and adiponectin findings and the publication bias clouding the HbA1c estimate. For now, the message for patients and clinicians is one of informed vigilance rather than alarm: keeping blood sugar in check remains fundamental to diabetes care, and the brain may be among the organs that benefit most.

Subject of Research: Associations between glycemic and metabolic biomarkers and cognitive impairment and dementia in elderly patients with diabetes

Article Title: Association of glycemic and metabolic biomarkers with cognitive impairment and dementia among elderly patients with diabetes: a systematic review and a dose-response meta-analysis

Article References: Liu, F., Zhang, P., Wu, G., Zhai, S., Zhang, J., Yu, X., Shen, C., & Wang, R. (2026). Association of glycemic and metabolic biomarkers with cognitive impairment and dementia among elderly patients with diabetes: a systematic review and a dose-response meta-analysis. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08513-4

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08513-4

Keywords: dementia, cognitive impairment, diabetes, HbA1c, fasting plasma glucose, TyG index, adiponectin, meta-analysis, geriatrics, blood sugar, insulin resistance, systematic review

The study, published in Frontiers in Behavioral Neuroscience, recruited 204 deaf adults aged 18 to 45 years in Amman, all of whom had congenital, profound bilateral hearing loss and used sign language as their primary means of communication. The researchers, led by Rand Alsharq of Applied Science Private University and Abeer Ahmad Bahathig of Northern Border University, went to considerable lengths to make the research genuinely accessible. Consent forms, questionnaires, and the entire psychological assessment were delivered in Jordanian Sign Language by certified interpreters, and all communication during the study was conducted exclusively in sign language. That methodological care matters, because psychological research in deaf populations has long been hampered by instruments that were never designed or validated for sign language users.

To measure psychological distress, the team used the Depression, Anxiety, and Stress Scale-21, a widely used 21-item questionnaire that yields separate scores for each of the three emotional states. Body composition was assessed with bioelectrical impedance analysis, providing detailed measurements of body fat percentage, visceral fat, lean mass, and skeletal muscle. Blood samples were drawn, centrifuged, and frozen, then analyzed with enzyme-linked immunosorbent assays to quantify serum concentrations of BDNF and adiponectin. The result was an unusually rich dataset linking psychology, metabolism, and molecular biology in a population that has been almost entirely overlooked in this literature.

The headline finding is striking. Serum BDNF levels showed strong inverse correlations with all three measures of distress: a correlation coefficient of −0.632 with anxiety, −0.732 with depression, and −0.795 with stress, all statistically significant at p < 0.001. In plain terms, the participants with the least BDNF in their blood reported the most severe psychological symptoms, and the relationship was remarkably tight. Adiponectin told a similar but weaker story, with inverse correlations of −0.422 for anxiety, −0.344 for depression, and −0.446 for stress. Because correlation alone cannot rule out confounding, the researchers then ran multiple linear regression models adjusted for age, sex, and body mass index. BDNF emerged as an independent negative predictor of all three outcomes, with standardized coefficients of −0.48 for anxiety, −0.55 for depression, and −0.62 for stress, and the full models explained between 36 and 42 percent of the variance in psychological scores.

Adiponectin, by contrast, survived the statistical adjustment only for anxiety (β = −0.19, p = 0.03) and stress (β = −0.21, p = 0.02). Its association with depression, while present in the raw correlations, lost statistical significance once demographic factors and body composition were taken into account. That attenuation is itself informative. It suggests that the apparent link between adiponectin and depressive symptoms in this sample is largely carried by factors such as adiposity, which is known to suppress circulating adiponectin. BDNF, meanwhile, appears to be the more robust molecular signature of psychological distress in this population, standing on its own regardless of body size.

Understanding why these molecules matter requires a brief tour of their biology. BDNF is a member of the neurotrophin family, a group of proteins that support the survival, growth, and connectivity of neurons. It is highly expressed in the hippocampus and prefrontal cortex, regions central to emotion regulation, and it underpins synaptic plasticity — the cellular machinery of learning, memory, and adaptive responses to stress. Chronic inflammation and prolonged psychological stress are known to suppress BDNF expression, impairing neuroplasticity and destabilizing emotional regulation. Decades of research have linked reduced BDNF concentrations to major depressive disorder, anxiety disorders, and stress-related conditions, particularly during acute episodes. The new study extends this framework to deaf adults, a group whose chronic exposure to communication stressors may plausibly feed into the same neurobiological pathway.

Adiponectin is a different beast altogether. Secreted by adipose tissue, it is best known as an anti-inflammatory, insulin-sensitizing, cardioprotective hormone — levels typically fall as body fat rises. But growing evidence points to a neuroprotective role as well, acting through pathways involving inflammation, oxidative stress, and neurotrophic signaling, including direct interactions with BDNF itself. Lower adiponectin has been reported in people with mood, anxiety, and stress-related disorders, and meta-analyses have generally found reduced levels in depression, although the literature is not unanimous. The Jordanian findings sit comfortably within this emerging picture, while adding the caveat that in deaf adults the adiponectin signal may be substantially mediated by body composition.

The study also documented a heavy burden of psychological distress in its own right. Moderate depression was the single most common severity category, affecting 40.2 percent of participants, with a further 19.1 percent in the severe range. Moderate anxiety was the most frequent anxiety category at 34.8 percent, and 38.2 percent of participants reported moderate stress. Sex differences emerged in the upper tail of the distributions: deaf women were significantly overrepresented in the very severe anxiety category and in the moderate, severe, and very severe stress categories, although depression severity did not differ between the sexes. The female participants also carried significantly more body fat on average — 43.9 percent, above the normal acceptable range — which the authors suggest may partly explain their elevated vulnerability, given the well-documented links between excess adiposity and emotional distress.

The authors are careful about what the study can and cannot show. As a cross-sectional design, it captures a single moment in time and cannot establish whether low BDNF and adiponectin cause psychological distress, whether distress depletes these molecules, or whether both are driven by some third factor. Physical activity was not assessed, and this is no small omission: exercise can acutely raise circulating BDNF and, with repeated training, enhance BDNF-related neuroplasticity through lactate signaling and the PGC-1α/FNDC5 pathway, so unmeasured variation in activity could have shaped the results. Diet, too, may influence both biomarkers. The sign language version of the DASS-21, while culturally and linguistically adapted by a certified researcher, has not yet been independently psychometrically validated in deaf adults. These limitations temper but do not erase the central finding, which the authors describe as the first demonstration that BDNF and adiponectin may serve as biomarkers of psychological distress in the deaf population.

The implications reach beyond biomarker hunting. If impaired neuroplasticity and inflammatory pathways genuinely contribute to the psychological burden carried by deaf adults, then interventions that boost these molecular systems — tailored nutrition, structured exercise, or targeted mental healthcare delivered in sign language — could offer a route to measurable relief. The authors call for prospective longitudinal studies to untangle causal direction and to test whether lifestyle interventions aimed at raising BDNF and adiponectin can alleviate distress in this population. For a community whose mental health needs have long been underserved and understudied, the idea that a simple blood test might one day help identify those at greatest risk is a small but genuinely hopeful step forward.

Subject of Research: Associations between serum BDNF and adiponectin and psychological distress in deaf adults

Article Title: Association of serum brain-derived neurotrophic factor and adiponectin with anxiety, depression, and stress in deaf adults: a cross-sectional study

Article References: Alsharq, R., AL-Dalaeen, A., Saleh, E., Batarseh, N., & Bahathig, A. A. (2026). Association of serum brain-derived neurotrophic factor and adiponectin with anxiety, depression, and stress in deaf adults: a cross-sectional study. Frontiers in Behavioral Neuroscience, 20, Article 1955159. https://doi.org/10.3389/fnbeh.2026.1955159

Image Credits: AI Generated

DOI: 10.3389/fnbeh.2026.1955159

Keywords: BDNF, adiponectin, deaf adults, anxiety, depression, stress, psychological distress, biomarkers, neuroplasticity, cross-sectional study, Jordan, mental health

At the heart of the review is the concept of metabolic homeostasis, the tightly regulated equilibrium of energy intake, storage and expenditure that keeps blood glucose, lipids and hormones within physiological ranges. The hypothalamic-pituitary-ovarian axis, which governs follicle development, ovulation and steroid hormone production, is exquisitely sensitive to this equilibrium. Nutritional status is relayed to the brain largely through adipokines such as leptin and adiponectin, which act on hypothalamic neurons including kisspeptin and AgRP neurons that gate the release of gonadotropin-releasing hormone. When energy stores are abundant or depleted, these signals shift, altering the timing of puberty, the regularity of menstrual cycles and the quality of ovulation.

Leptin, secreted by adipose tissue in proportion to fat mass, provides a permissive signal for the onset of puberty and for maintaining adult fertility. Experimental work in mice shows that leptin signalling in AgRP neurons modulates puberty onset and that AgRP-to-Kiss1 neuron communication links nutritional state to fertility. In the ovary itself, leptin has modulatory effects on steroidogenesis in granulosa and theca cells, and it can antagonise the insulin-like growth factor I augmentation of steroidogenesis. Adiponectin, by contrast, is generally insulin-sensitising and anti-inflammatory, and its deficiency in mice leads to female subfertility and ovarian dysfunction. Low adiponectin levels are consistently observed in women with polycystic ovary syndrome, and recent systematic reviews in adolescent girls reinforce this association.

Estrogen emerges as a central regulator of energy homeostasis. It improves insulin sensitivity and suppresses hepatic gluconeogenesis through the transcription factor Foxo1, and an estrogen receptor alpha-derived peptide has been shown to improve glucose homeostasis during obesity. Estrogen also regulates adipose tissue health, influencing fat distribution and adipokine secretion. This relationship runs in both directions: adipose tissue expresses aromatase, converting androgens to estrogens, and women with metabolic dysfunction show increased adipose indices of androgen catabolism and aromatization. The liver, meanwhile, produces sex hormone-binding globulin, the primary gatekeeper of steroid hormone action, whose expression is suppressed by inflammatory cytokines such as IL-1β and TNFα and by insulin resistance, thereby increasing free androgen and estrogen bioavailability.

The review pays particular attention to polycystic ovary syndrome, recently renamed polyendocrine metabolic ovarian syndrome following a multistep global consensus process. This renaming reflects the recognition that the condition is not merely an ovarian disorder but a systemic metabolic-endocrine disease. Women with the syndrome have substantially elevated rates of metabolic syndrome, insulin resistance, type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Longitudinal data from a United Kingdom primary care database demonstrated that androgen excess in these women predicts nonalcoholic fatty liver disease, and Mendelian randomisation analyses suggest causal links between sex hormones and hepatic fat accumulation. Conversely, androgens exacerbate hepatic triglyceride accumulation by downregulating microsomal triglyceride transfer protein, and dihydrotestosterone induces liver steatosis via transcriptional regulation of SCAP in normal-weight female mice.

Reproductive ageing represents another critical intersection. Follicle-stimulating hormone, which rises as ovarian reserve declines, has been shown to regulate fat accumulation and redistribution in ageing through the Gαi/Ca²⁺/CREB pathway, to enhance hepatic gluconeogenesis via GRK2-mediated AMPK hyperphosphorylation, and to induce postmenopausal dyslipidemia by inhibiting hepatic cholesterol metabolism. Blocking FSH has been shown to inhibit hepatic cholesterol biosynthesis and reduce serum cholesterol in experimental models. These findings suggest that the hormonal shifts of the menopausal transition are not merely passive consequences of ovarian ageing but active drivers of cardiometabolic risk, helping to explain why cardiovascular disease risk accelerates after menopause.

Pregnancy adds a further layer of complexity. Gestational diabetes mellitus affects a substantial proportion of pregnancies worldwide, and maternal insulin resistance is associated with placental miR-3940-3p expression in late pregnancy. Insulin-mediated immune dysfunction has been implicated in the development of preeclampsia, and maternal obesity increases the risk of preterm delivery. The review also highlights that a history of miscarriage or stillbirth predicts future diabetes risk, while preterm birth and low birth weight are associated with nonalcoholic fatty liver disease in community-based cohorts. These bidirectional associations underscore that metabolic and reproductive health are intertwined from preconception through postmenopause.

On the therapeutic front, the review critically evaluates lifestyle interventions, metabolic surgery and pharmacological therapies. Time-restricted eating has been tested in a randomised controlled trial for body weight management in women with polycystic ovary syndrome, and ketogenic diets have been systematically reviewed for their effects on the condition. Exercise interventions, particularly high-intensity training, show promise for improving both cardiometabolic and reproductive outcomes. Bariatric surgery has been shown in the BAMBINI multicentre randomised controlled trial to restore spontaneous ovulation in women living with polycystic ovary syndrome and obesity. Among pharmacological options, metformin remains a mainstay, with evidence supporting its role in ovulation induction and metabolic improvement, though questions remain about its long-term effects on offspring growth when used during pregnancy.

Glucagon-like peptide-1 receptor agonists represent a rapidly evolving therapeutic class. Liraglutide has been shown in randomised studies to improve weight, body composition and hormonal parameters in women with obesity and polycystic ovary syndrome, and to increase IVF pregnancy rates in poor responders. Combination therapy with metformin and semaglutide has shown promise in prospective randomised trials, and preclinical work suggests that GLP-1-based multi-agonist therapy may offer superior metabolic improvement of polycystic ovary syndrome traits compared with single-agent approaches. Sodium-glucose cotransporter inhibitors, including canagliflozin, have also been evaluated in randomised trials and show noninferiority to metformin in certain metabolic endpoints. The review notes that these agents may act not only through weight loss but also through direct effects on ovarian GLP-1 receptors and the gut-gonadal axis.

Looking forward, the authors emphasise precision approaches that account for genetic and epigenetic heterogeneity. Variants in genes such as THADA, INSR, TOX3 and DENND1A have been linked to metabolic syndrome or insulin resistance in women with polycystic ovary syndrome, and DNA methylation of the AMHRII and INSR genes has been associated with disease pathogenesis. Environmental exposures, including per- and polyfluoroalkyl substances in drinking water, have been linked to gestational diabetes, hypertension and preeclampsia in nationwide register-based studies. The review concludes that reframing female reproductive disorders from a systemic metabolic perspective offers a path toward more effective, personalised interventions that address both reproductive and cardiometabolic outcomes simultaneously, rather than treating them as separate clinical domains.

Subject of Research: The bidirectional relationship between metabolic homeostasis and female reproductive function across the life course

Article Title: Metabolic homeostasis and women’s reproductive health

Article References: Liu, X., Yang, L., Jiang, J., Chang, H.-M., & Mu, L. (2026). Metabolic homeostasis and women’s reproductive health. Nature Metabolism. https://doi.org/10.1038/s42255-026-01646-1

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01646-1

Keywords: metabolic homeostasis, women's reproductive health, polycystic ovary syndrome, polyendocrine metabolic ovarian syndrome, insulin resistance, leptin, adiponectin, estrogen, GLP-1 receptor agonists, metformin, reproductive ageing, gestational diabetes

The research team, led by Elnaz Harooni and colleagues at Ahvaz Jundishapur University of Medical Sciences in Iran, focused on a well-established experimental approach: the letrozole-induced PCOS mouse. Letrozole is a nonsteroidal inhibitor of aromatase, the enzyme encoded by the Cyp19a1 gene that converts testosterone into estrogen. By blocking estrogen production, letrozole causes androgens to accumulate in female rodents, producing a cluster of symptoms that closely mirrors human PCOS, including androgen excess, elevated blood glucose, abnormal follicle development, and oxidative stress. The researchers administered letrozole orally at 6 milligrams per kilogram of body weight for 21 consecutive days to adult female NMRI mice, then confirmed the PCOS phenotype through daily vaginal smear cytology, which revealed disrupted and arrested estrous cycles in the treated animals.

Lauric acid is a medium-chain fatty acid that accounts for roughly 45 to 53 percent of coconut oil and is widely credited with many of the oil’s reported health benefits, from improved cognitive function in Alzheimer’s disease to reduced cardiovascular risk. Previous work has shown that lauric acid can lower body weight, improve lipid profiles, and enhance insulin sensitivity, effects that have been linked to activation of the Sirt1/AMPK signaling pathway in the liver. That pathway is central to cellular energy sensing: AMP-activated protein kinase, or AMPK, monitors intracellular energy status and maintains energy homeostasis at both the cellular and whole-body levels, while sirtuin 1, or Sirt1, is an NAD-dependent histone deacetylase involved in glucose and lipid metabolism, oxidative stress regulation, and reproductive function. Notably, Sirt1 expression in the ovary is reduced in both human PCOS patients and animal models, making the Sirt1/AMPK axis an attractive therapeutic target.

In the new experiment, forty mice were divided into four groups of ten: a normal control group, a group receiving lauric acid alone, a PCOS group receiving letrozole followed by vehicle, and a PCOS group treated with lauric acid at 150 milligrams per kilogram per day for 15 days after PCOS induction. The dose was selected on the basis of prior studies demonstrating its efficacy and safety across a wide range. The results were striking in several domains. Lauric acid treatment significantly lowered fasting blood glucose and fasting insulin concentrations in the PCOS mice, and it significantly improved both the HOMA-IR index, a standard measure of insulin resistance, and the QUICKI index, which reflects insulin sensitivity. Given that compensatory hyperinsulinemia drives many PCOS features and increases the risk of cardiovascular disease and type 2 diabetes, this metabolic improvement is clinically meaningful.

The fatty acid also reshaped the hormonal landscape of the treated animals. Letrozole had produced the classic PCOS hormonal signature: elevated luteinizing hormone, an increased LH-to-FSH ratio, and raised testosterone, accompanied by reduced follicle-stimulating hormone, progesterone, and estradiol. Fifteen days of lauric acid administration significantly decreased testosterone, LH, and the LH/FSH ratio while significantly raising estradiol levels. Mechanistically, this appears to involve restoration of the aromatase machinery: lauric acid significantly reversed the letrozole-driven decline in ovarian Cyp19a1 protein expression, the very enzyme the drug inhibits, while simultaneously reducing the elevated expression of ovarian androgen receptors that had heightened the animals’ sensitivity to accumulated androgens. Progesterone levels, however, remained depressed despite treatment, a limitation the authors openly acknowledge.

Lipid metabolism responded robustly as well. PCOS mice showed markedly elevated triglycerides and LDL cholesterol alongside reduced HDL cholesterol, a dyslipidemic pattern that mirrors the cardiovascular risk profile of human patients. Lauric acid treatment significantly increased HDL cholesterol and reduced both LDL cholesterol and triglycerides, and it significantly lowered the atherogenic index, a logarithmic marker of cardiometabolic risk calculated from the triglyceride-to-HDL ratio. Interestingly, lauric acid improved this index even in healthy mice, suggesting the fatty acid may beneficially modulate lipid handling independent of disease state. Consistent with these findings, the expression of two key adipose tissue regulators, adiponectin and peroxisome proliferator-activated receptor gamma, or PPARγ, was sharply reduced in the white adipose tissue of PCOS mice and significantly restored by lauric acid treatment. These molecules cooperate in regulating glucose and lipid homeostasis, and their upregulation may partially explain the observed improvements in insulin sensitivity.

The study also probed the oxidative and structural consequences of the disease. Ovaries from PCOS mice contained significantly higher concentrations of malondialdehyde, a lipid peroxidation product, and significantly lower total antioxidant capacity, reflecting the oxidant-antioxidant imbalance known to impair oocyte maturation, ovulation, and fertilization. Lauric acid treatment shifted both markers back toward normal. Histological examination told a parallel story: letrozole produced large ovarian cysts and drastically reduced the number of healthy and antral follicles, whereas lauric acid-treated mice showed fewer cystic follicles and a significant recovery of antral follicle formation, indicating a partial resumption of follicular development. Western blot analysis provided the molecular capstone, revealing that lauric acid significantly restored the letrozole-suppressed expression of Sirt1 and AMPK proteins within ovarian tissue.

The authors propose that these molecular changes form a coherent mechanism. Sirt1 is known to regulate aromatase expression in granulosa cells and to protect both pancreatic beta cells and ovarian granulosa cells through antioxidant and anti-inflammatory actions, while the Sirt1/AMPK pathway has been directly implicated in the insulin resistance of PCOS. The restoration of GLP-1, a gut-derived incretin hormone that fell significantly in PCOS mice and rebounded with lauric acid treatment, adds another layer, since GLP-1 receptor agonists are increasingly used to manage PCOS and have been linked to enhanced adiponectin and PPARγ activity. Not every parameter responded, however. Body weight gain induced by letrozole was not reversed, spexin, another metabolic hormone, remained unchanged, and the improvement in estrous cyclicity, though notable, with 60 percent of treated mice showing normal cycles versus 30 percent of untreated PCOS mice, did not reach statistical significance.

As the authors emphasize, this is the first study to evaluate lauric acid in a letrozole-induced PCOS model, and the findings should be interpreted as preliminary. The work was conducted in mice over a short treatment window, and the improvements, while broad, were partial and inconsistent across all measured endpoints. Translating a 150 milligram per kilogram daily dose into a safe and effective human regimen would require extensive dose-ranging, pharmacokinetic, and safety studies, and the relationship between dietary coconut oil consumption and purified lauric acid supplementation is far from straightforward. Nevertheless, the convergence of evidence, improved insulin sensitivity, corrected dyslipidemia, partially restored sex hormones, reduced oxidative stress, healthier ovarian histology, and reactivated Sirt1/AMPK signaling, positions lauric acid as a compelling candidate for further investigation as a complementary agent against the metabolic and endocrine disturbances of PCOS. Larger and longer studies will be needed to confirm whether this humble coconut-derived fatty acid can truly deliver on that promise.

Subject of Research: Effects of lauric acid on endocrine and metabolic alterations in a letrozole-induced mouse model of polycystic ovary syndrome

Article Title: Lauric acid ameliorates endocrine-metabolic alterations in letrozole-induced polycystic ovary syndrome in female mice

Article References: Harooni, E., Ahangarpour, A., Khorsandi, L., & Mard, S. A. (2026). Lauric acid ameliorates endocrine-metabolic alterations in letrozole-induced polycystic ovary syndrome in female mice. Heliyon, 12(15), Article e45556. https://doi.org/10.1016/j.heliyon.2026.e45556

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45556

Keywords: PCOS, lauric acid, coconut oil, Sirt1, AMPK, insulin resistance, letrozole, hyperandrogenism, adiponectin, PPAR gamma, oxidative stress, mouse model

The research, led by Xia Sun and Tianrong Pan of the Second Affiliated Hospital of Anhui Medical University along with colleagues at Lishui Hospital of Traditional Chinese Medicine, took a retrospective look at 150 patients with type 2 diabetes who were treated at a tertiary hospital between January 2022 and December 2023. All patients met the 1999 World Health Organization diagnostic criteria for diabetes. Of the 150 individuals in the cohort, 92 had already developed diabetic retinopathy, giving the researchers a substantial group of both affected and unaffected patients to compare. The goal was not simply to catalog differences between the two groups but to build a working mathematical model that could estimate an individual patient’s risk.

The scientific rationale behind the study rests on a growing body of evidence that diabetic retinopathy is not merely a disease of high blood sugar damaging tiny retinal vessels. Subclinical inflammation and endothelial dysfunction—the gradual breakdown of the delicate inner lining of blood vessels—appear to play central roles in the earliest stages of retinal injury. Two families of biological markers have attracted attention in this context. The first is adipokines, signaling molecules secreted by adipose tissue that influence metabolism, inflammation, and vascular health. The second is hematological indices, particularly red cell distribution width, or RDW, a measure of the variation in the size of circulating red blood cells that has increasingly been recognized as a marker of systemic inflammation and oxidative stress.

Among the adipokines examined were omentin-1, adiponectin, apelin, and nesfatin-1, each with distinct and sometimes counterintuitive relationships to retinal disease. Using multivariate logistic regression, the researchers found that higher levels of omentin-1 and apelin were associated with an increased risk of diabetic retinopathy, while higher nesfatin-1 levels were associated with a reduced risk. Adiponectin, one of the most extensively studied fat-derived hormones, was incorporated into the final prediction model as well. The findings underscore how complex the biology of adipose tissue is in diabetes: molecules that are often described as protective in metabolic disease can behave differently when viewed through the lens of microvascular complications.

The hematological and biochemical picture that emerged was equally instructive. Patients with a mean arterial pressure above 120 mmHg faced elevated risk, as did those with abnormal levels of the liver enzymes aspartate aminotransferase and gamma-glutamyl transpeptidase, and those with high blood urea nitrogen, a marker of kidney function. Conversely, several factors appeared protective in the statistical analysis: higher high-density lipoprotein cholesterol, abnormal alanine aminotransferase, and high insulin resistance as measured by the homeostasis model assessment were each associated with reduced risk of retinopathy. Some of these associations—particularly the counterintuitive direction of the insulin resistance finding—highlight the hazards of interpreting retrospective data and the need for caution before drawing biological conclusions.

To translate these associations into a practical tool, the team constructed a prediction model and evaluated its performance using receiver operating characteristic analysis, the standard method for assessing how well a diagnostic or prognostic model separates those who develop a condition from those who do not. The apparent area under the curve, or AUC, was 0.921 with a 95 percent confidence interval of 0.880 to 0.962, a figure that in clinical terms suggests excellent discrimination. Because apparent performance almost always overstates how a model will behave in new patients, the researchers applied bootstrap internal validation, a resampling technique that estimates the degree of overfitting. The optimism-corrected AUC came out at 0.873 with a confidence interval of 0.821 to 0.925, still comfortably in the range considered good for a clinical prediction model.

Discrimination, however, is only half the story. A prediction model must also be well calibrated, meaning that when it says a patient has a 40 percent risk, roughly 40 percent of similar patients should actually develop the disease. The Hosmer-Lemeshow test suggested adequate calibration with a p value of 0.293, but the more visually informative calibration plot told a subtler tale. The model systematically underestimated risk in the intermediate probability range between 0.2 and 0.6 and overestimated risk around the 0.7 mark. The authors were candid about this discrepancy, describing the calibration as suboptimal and flagging it as an issue that would need to be addressed before any clinical deployment. This kind of transparency is increasingly valued in the prediction-model literature, where inflated claims of readiness have historically undermined trust in such tools.

The researchers also performed decision-curve analysis, a technique that quantifies the net benefit of using a model to guide clinical decisions across a range of risk thresholds. The model demonstrated positive net benefit across threshold probabilities of 10 percent to 60 percent, suggesting that within that band, acting on the model’s predictions would yield more benefit than the default strategies of treating all patients or treating none. In practical terms, this means an ophthalmology or endocrinology service could, in principle, use the model to prioritize patients for retinal screening, reserving scarce imaging and specialist resources for those whose calculated risk justifies closer surveillance.

Despite the encouraging numbers, the authors are careful to frame the study as a starting point rather than a finished clinical instrument. The cohort was modest in size, drawn from a single tertiary hospital, and analyzed retrospectively, all of which limit generalizability. The model has not yet been tested in an independent external cohort, the gold standard for demonstrating that a prediction tool performs as advertised outside the data that shaped it. The authors explicitly state that external validation and model recalibration are needed before clinical application. The calibration deviations observed in the intermediate risk range, where most clinical decisions are actually made, reinforce that recommendation.

Even with those caveats, the study adds to a compelling trend in diabetes research: the search for affordable, widely available biomarkers that can stratify risk before irreversible damage occurs. Adipokines and RDW can be measured from standard blood samples in most hospital laboratories, and combining them with blood pressure, liver enzymes, and kidney markers requires no new technology. If future prospective studies confirm the model’s performance and correct its calibration, the approach could help shift diabetic retinopathy care from reactive screening toward proactive risk management, catching the disease in time to preserve vision for the millions of people living with type 2 diabetes worldwide.

Subject of Research: A clinical prediction model for diabetic retinopathy in type 2 diabetes using adipokines and red cell distribution width

Article Title: A prediction model for diabetic retinopathy incorporating adipokines and red cell distribution width among patients with type 2 diabetes

Article References: Sun, X., Qiu, W., Chen, X., Zheng, P., Dan, L., Wu, J., & Pan, T. (2026). A prediction model for diabetic retinopathy incorporating adipokines and red cell distribution width among patients with type 2 diabetes. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02546-x

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02546-x

Keywords: diabetic retinopathy, type 2 diabetes, adipokines, omentin-1, adiponectin, red cell distribution width, prediction model, apelin, nesfatin-1, logistic regression, ROC analysis, endothelial dysfunction

To understand why this finding matters, it helps to start with adiponectin itself. Adiponectin is a hormone secreted almost exclusively by adipocytes, the fat cells of adipose tissue, and it circulates in remarkably high concentrations in the bloodstream. For years it has been celebrated as a protective adipokine: levels tend to fall in obesity, insulin resistance and type 2 diabetes, and restoring its signaling has been a long-standing therapeutic ambition. Adiponectin exerts its effects by binding to two G-protein-coupled-like receptors, AdipoR1 and AdipoR2, which in turn engage intracellular cascades including AMP-activated protein kinase, or AMPK, a central metabolic master switch. AdipoRon, developed as an orally available small-molecule agonist of these receptors, was designed to mimic adiponectin’s beneficial metabolic actions in patients whose adiponectin signaling is impaired.

Yet adiponectin biology has never been a simple story of good versus bad. The correspondence sits within a literature that documents strikingly context-dependent, even contradictory, effects of the hormone. Shibata, Ouchi, Kihara and colleagues showed in the Journal of Biological Chemistry in 2004 that adiponectin actually stimulates angiogenesis in response to tissue ischemia through AMPK signaling, a beneficial effect when the goal is revascularizing starving tissue. Man, Ng, Xu and colleagues reported in Clinical Cancer Research in 2010 that adiponectin suppresses liver tumor growth and metastasis in nude mice by inhibiting tumor angiogenesis and downregulating Rho kinase, interferon-inducible protein 10 and matrix metalloproteinase 9 signaling, an anti-angiogenic effect in that setting. Cai, Xu, Piao and colleagues demonstrated in Molecular Carcinogenesis in 2016 that adiponectin can induce CXCL1 secretion from cancer cells and promote tumor angiogenesis by driving stromal fibroblast senescence. Roy and Palaniyandi, reviewing the field in Cell Bioscience in 2021, emphasized that adiponectin’s downstream signaling pathways are profoundly tissue-specific. In other words, the same receptor-ligand system can build vessels in one context and strangle them in another.

Against that backdrop, the original article by Mallardo and colleagues made a provocative claim: in B-cell leukemia, activation of adiponectin signaling with AdipoRon does not restrain the disease but instead promotes angiogenesis, and it does so by shifting the balance of pro-angiogenic factors through AdipoR1 specifically. B-cell leukemias, including chronic lymphocytic leukemia and related lymphoproliferative disorders, depend on their microenvironment for survival signals, and the formation of new blood vessels within leukemic niches supplies not only oxygen and nutrients but also paracrine support that can protect malignant cells from chemotherapy. If a diabetes-oriented drug candidate were to enhance that vascular supply, the implications for patient safety would be immediate and serious, particularly because AdipoRon has been proposed in some quarters as a candidate for repurposing in metabolic disease and, paradoxically, in cancer contexts where adiponectin signaling was assumed to be protective.

The mechanistic detail highlighted in the correspondence, that the pro-angiogenic effect is mediated through AdipoR1 rather than AdipoR2, is significant for drug development. The two receptors are not interchangeable. AdipoR1 is generally described as the more abundant isoform in skeletal muscle and is more tightly coupled to AMPK activation, whereas AdipoR2 is more prominent in the liver and is associated with peroxisome proliferator-activated receptor alpha signaling. A compound whose vascular effects run through AdipoR1 therefore engages the very arm of the pathway most associated with metabolic benefit, which complicates any simple strategy of dialing adiponectin signaling up or down. It also suggests that receptor-selective ligands, rather than broad agonists, may be needed if adiponectin-based therapeutics are to be deployed safely in patients who may harbor occult hematologic malignancies.

What makes the Padulo correspondence particularly noteworthy, however, is not only its endorsement of the biological finding but the methodological lens through which it examines the work. The correspondence’s reference list is telling: alongside the original article and the adiponectin literature, it cites Begley and Ellis’s landmark 2012 Nature commentary urging higher standards for preclinical cancer research, Nuzzo’s 2014 Nature news feature on statistical errors in science, and Padulo’s own 2014 Proceedings of the National Academy of Sciences letter on distinguishing signal from noise in statistical analysis. This trio of citations signals a correspondence concerned with reproducibility, statistical power and the interpretation of noisy biological data, issues that have dogged preclinical oncology for over a decade. Begley and Ellis famously reported that industry scientists could replicate only a small fraction of published preclinical cancer findings, and their call for rigor, blinding, replication and transparent statistics has since become a benchmark against which new mechanistic claims are measured.

Reading the correspondence in that light, its contribution is twofold. First, it draws attention to a genuinely surprising result that challenges the prevailing assumption that adiponectin signaling is uniformly tumor-suppressive in hematologic malignancy. Second, it implicitly frames the original finding as a test case for how the field should handle results that cut against expectation: with rigorous statistics, careful receptor-level mechanistic dissection and an awareness of the tissue-specific contingencies documented across the adiponectin literature. The correspondence states that no datasets were generated or analysed during its preparation, confirming its role as a commentary and critique rather than a new experimental study, and its author declares no competing interests. The original article, published a year earlier, remains the primary source of the experimental evidence linking AdipoRon, AdipoR1 and pro-angiogenic factor modulation in B-cell leukemia cells.

For clinicians and translational researchers, the stakes are concrete. AdipoRon has been widely discussed as a potential therapy for metabolic syndrome, and adiponectin agonism has been explored for cardiovascular protection, where promoting angiogenesis in ischemic tissue would be a feature rather than a bug. But a substantial fraction of patients with metabolic disease are older adults, the same demographic in which B-cell leukemias and indolent lymphomas are most common, often undiagnosed and slowly progressive. A drug that stimulates vessel formation within a leukemic niche could, in principle, accelerate disease progression in precisely the population most likely to receive it. The correspondence therefore functions as a safety flag: before adiponectin receptor agonists move further toward the clinic, their effects on hematologic malignancy microenvironments need to be characterized as thoroughly as their metabolic benefits.

For basic scientists, the finding adds a compelling data point to the growing map of adiponectin’s dual personality. The hormone that protects the heart and liver in one setting can feed a tumor’s blood supply in another, and the deciding variable appears to be tissue context, receptor isoform and the specific pro-angiogenic factors a given malignancy deploys. Disentangling which downstream mediators, AMPK and beyond, are recruited in B-cell leukemia cells, and which pro-angiogenic factors rise when AdipoR1 is engaged, will be the obvious next step for experimental follow-up. The correspondence’s emphasis on statistical rigor suggests that such follow-up should be designed with adequate power, independent replication and pre-specified endpoints from the outset.

The exchange also illustrates the healthy function of correspondence sections in scientific journals. A single letter, published on 7 October 2026 in volume 53 of Molecular Biology Reports as article number 1674, can reframe a year-old experimental finding, connect it to a decade-long conversation about reproducibility in cancer research, and redirect the attention of both drug developers and hematologists toward an underappreciated risk. Whether AdipoRon ultimately proves to be a metabolic wonder drug, a vascular hazard for leukemia patients or both, the dialogue between the original authors and their correspondent has already clarified the questions that must be answered next: which receptor, which factors, which context, and how confident can we be that the signal is real.

Subject of Research: Adiponectin receptor signaling and angiogenesis in B-cell leukemia

Article Title: Correspondence to: AdipoRon promotes angiogenesis in B-cell leukemia by modulating pro-angiogenic factors through AdipoR1

Article References: Padulo, J. (2026). Correspondence to: AdipoRon promotes angiogenesis in B-cell leukemia by modulating pro-angiogenic factors through AdipoR1. Molecular Biology Reports, 53(1), Article 1674. https://doi.org/10.1007/s11033-026-12845-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12845-0

Keywords: AdipoRon, adiponectin, AdipoR1, angiogenesis, B-cell leukemia, AMPK, pro-angiogenic factors, tumor microenvironment, Molecular Biology Reports, preclinical research, reproducibility, drug repurposing

Adipokines have long been the province of metabolic research rather than emergency medicine. These molecules, secreted by white adipose tissue, act as chemical messengers that influence appetite, insulin sensitivity, and immune activity throughout the body. Among the most studied are adiponectin, which generally exerts anti-inflammatory and protective effects on blood vessels and kidneys, and resistin, which in humans is produced largely by immune cells and is strongly associated with inflammatory activation. Leptin and retinol-binding protein 4 round out the panel, each carrying its own metabolic and immunological signatures. What has remained unclear is how this hormonal ensemble behaves in the acute chaos of major trauma, and whether its behavior carries any clinical meaning for patients fighting for their lives in intensive care.

To find out, the Ulm team, led by Lena Schütte and Rebecca Halbgebauer, conducted a secondary retrospective analysis of a longitudinal observational cohort, drawing on prospectively collected plasma samples and clinical data from 67 patients with an Injury Severity Score of at least 16, a threshold defining severe polytrauma. They compared these patients with 31 healthy volunteers. Blood was drawn at four time points: on admission to hospital, and then on days one, five, and ten. At each point, the researchers measured circulating levels of resistin, adiponectin, leptin, and retinol-binding protein 4, alongside a battery of inflammatory markers and clinical indicators of organ function.

The statistical approach was deliberately rigorous. Because adipokine levels are known to vary with body composition, age, and sex, the team used linear mixed-effects models adjusted for age, sex, body mass index, and waist-to-hip ratio, the latter derived from computed tomography scans as a measure of body-fat distribution. Associations with inflammatory markers and organ dysfunction were assessed using partial Spearman correlations, and the researchers applied false discovery rate correction to guard against spurious findings that arise when many comparisons are made simultaneously. Exploratory receiver-operating characteristic analyses were then used to ask whether adipokine measurements could classify clinically meaningful outcomes, including length of hospital stay, length of intensive care stay, shock severity, and 30-day mortality.

The results were striking from the very first blood draw. Compared with healthy volunteers, trauma patients arrived at the hospital with a fundamentally altered adipokine profile: resistin was significantly elevated, while adiponectin was significantly reduced. This reciprocal shift, an increase in a pro-inflammatory signal paired with a decrease in a protective one, suggests that severe injury rapidly reprograms the endocrine output of fat tissue and the immune cells that produce these hormones. The changes were not subtle statistical whispers but robust differences detectable at admission, before most clinical interventions had time to exert their own effects on the circulating hormone landscape.

Perhaps the most compelling finding was the strength of the relationship between resistin and interleukin-6, one of the central cytokines driving the post-traumatic inflammatory response. At admission, resistin levels correlated with IL-6 at approximately 0.75, a correlation strong enough to survive false discovery rate correction. In biological terms, this means that patients whose blood carried the highest resistin concentrations were also mounting the most intense inflammatory responses. Resistin, in this context, appears less as a bystander and more as a potential readout of the immune system’s overall state of activation in the hours following injury.

When the researchers combined the two opposing signals into a single metric, the resistin-to-adiponectin ratio, they found the most consistent pattern of associations across the entire study. This ratio tracked with both inflammatory parameters and markers of renal dysfunction, including measures of kidney function such as estimated glomerular filtration. The kidney connection is particularly intriguing, because adiponectin has well-documented protective effects on renal tissue, and acute kidney injury is one of the most common and dangerous complications of severe trauma. A falling adiponectin level paired with rising resistin may therefore reflect, or even contribute to, the vulnerability of the kidneys during the critical early days after injury.

The exploratory outcome analyses offered cautious grounds for optimism, tempered by important limitations. Several adipokine measures showed moderate ability to classify selected clinical outcomes, such as length of hospital or intensive care stay and shock severity, in receiver-operating characteristic analyses. However, the mortality analyses were hampered by the small number of death events available at the later time points, making any conclusion about predicting survival statistically fragile. The authors are explicit that these outcome associations are exploratory and require prospective, multicenter validation before any claim of added clinical value beyond conventional parameters, such as the Sequential Organ Failure Assessment score, can be made.

One of the study’s secondary questions concerned whether body-fat distribution shapes the adipokine response to trauma. Using CT-derived waist-to-hip ratios, the researchers stratified patients and looked for differences in hormone profiles. For the most part, the stratified comparisons showed no clear separation across groups, suggesting that the dramatic adipokine shifts triggered by severe injury may override the more gradual influence of body composition, at least within the first ten days. This is a useful negative finding, because it implies that the trauma-induced adipokine signature could potentially serve as a standardized marker across patients of varying body types, though the authors note that most WHR-stratified differences were limited.

The broader significance of this work lies in its reframing of fat tissue as an active participant in the response to injury rather than a passive energy depot. The concept of immunometabolism, the interplay between immune signaling and metabolic regulation, has gained momentum across critical care research, and this study provides some of the most detailed longitudinal human data on adipokines in polytrauma to date. If future multicenter studies confirm that the resistin-to-adiponectin ratio adds predictive power for organ dysfunction beyond existing clinical scores, it could eventually help clinicians identify, within hours of admission, which patients are most likely to develop kidney injury or multi-organ dysfunction, opening a window for earlier and more targeted interventions. For now, the message is one of careful promise: the body’s fat-derived hormones respond to trauma with remarkable speed and specificity, and their story is only beginning to be told.

Subject of Research: Adipokine dynamics and their association with inflammation and acute organ dysfunction after severe polytrauma

Article Title: Inflammation-linked adipokine profiles associate with acute organ dysfunction after severe trauma

Article References: Schütte, L., Oßwald, K., Mannes, M., Wohlgemuth, L., Kumral, E., Mayer, B., Bülow, J. M., Bergmann, C. B., Relja, B., Gebhard, F., Huber-Lang, M., Fischer-Posovszky, P., Rayatdoost, F., & Halbgebauer, R. (2026). Inflammation-linked adipokine profiles associate with acute organ dysfunction after severe trauma. Journal of Translational Medicine, 24(1), Article 1176. https://doi.org/10.1186/s12967-026-08968-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08968-4

Keywords: adipokines, polytrauma, resistin, adiponectin, inflammation, organ dysfunction, acute kidney injury, interleukin-6, biomarkers, immunometabolism, intensive care, trauma surgery

The work, published in the Journal of Eating Disorders, emerges from the Norwegian Microbiota Study in Anorexia Nervosa, known as NORMA, a project funded by the Norwegian Research Council that examines how gut biology and eating disorders intersect. The team, led by Ida Heir Hovland and Siv Kjølsrud Bøhn of the Norwegian University of Life Sciences together with collaborators at Oslo University Hospital and other Norwegian centers, and including eating disorders researcher Cynthia M. Bulik of the Karolinska Institutet and the University of North Carolina at Chapel Hill, enrolled 42 patients with anorexia nervosa admitted for inpatient treatment and 42 age-matched healthy controls. Blood samples were drawn from patients at baseline, after six weeks, and after twelve weeks of treatment, while the healthy controls provided a single baseline sample for comparison.

The analytical approach was deliberately broad. Using Luminex technology, a bead-based immunoassay platform that can quantify many proteins simultaneously in a small volume of serum, the researchers measured an array of hormones and signaling molecules central to appetite regulation: ghrelin, the stomach-derived hormone that stirs hunger; leptin, the fat-cell hormone that signals long-term energy stores; insulin and C-peptide, markers of pancreatic insulin secretion; adipsin and resistin, adipose-derived factors; adiponectin, another fat-cell hormone with metabolic and anti-inflammatory roles; the incretin hormones GLP-1 and GIP, which are released by the gut after eating and modulate insulin secretion and satiety; glucagon; plasminogen activator inhibitor-1; and visfatin. Dietary intake was captured with a three-day digital food diary and interview, allowing the team to connect hormone levels not just to weight but to what patients actually ate.

The baseline differences were striking. Compared with healthy controls, patients with anorexia nervosa showed significantly lower levels of adipsin, leptin, insulin, and resistin, and significantly higher levels of adiponectin and glucose-dependent insulinotropic polypeptide, or GIP. Ghrelin, the hunger hormone, was also elevated in patients, though the difference fell just short of statistical significance with a p-value of 0.08. No baseline differences emerged for C-peptide, plasminogen activator inhibitor-1, or visfatin. Intriguingly, the size of the group difference in GLP-1 and glucagon depended on age, with discrepancies between patients and controls being greater in older participants, a hint that the hormonal signature of the illness may shift across the lifespan.

These patterns make physiological sense in the context of severe starvation. Leptin is produced by adipose tissue in proportion to fat stores, so its near-absence in emaciated patients is expected. Low insulin reflects reduced nutrient intake and reduced body fat. Elevated ghrelin is the body’s classic cry for food. But the elevated adiponectin and GIP are less intuitive, and their persistence raises questions about whether the gut–brain axis in anorexia nervosa is merely responding to starvation or has been fundamentally rewired by it. Adiponectin typically rises as fat mass falls, yet its other roles in inflammation and energy metabolism suggest it may be doing more than simply tracking body composition.

Then came treatment. Over twelve weeks of structured inpatient care, designed around nutritional rehabilitation, the patients’ mean body mass index rose significantly from 15.5 to 18.2 kilograms per square meter, a substantial gain that nonetheless left most patients below the healthy BMI range. The hormonal response to this refeeding was a study in partial recovery. Adipsin, leptin, insulin, and C-peptide all increased, moving in the direction of healthy control values. Ghrelin decreased and approached the levels seen in controls. In other words, the hormones most tightly coupled to fat mass and acute nutrient flux responded to treatment much as one would predict from basic endocrinology.

But four signals stood apart. Glucagon, adiponectin, GIP, and GLP-1 were largely resistant to change across the twelve weeks of treatment. These are precisely the hormones most entangled with the gut side of the gut–brain axis: GLP-1 and GIP are secreted by intestinal enteroendocrine cells in response to food, and glucagon, produced by the pancreatic alpha cells, governs glucose mobilization during fasting. Their stubbornness suggests that refeeding and weight gain, at least over this timeframe, are not sufficient to normalize every arm of the appetite-signaling network. The authors interpret this as evidence of continued gut–brain axis dysregulation, a molecular echo of the illness that persists even as the body is refed.

Perhaps the most consequential finding of the study concerns diet. When the researchers examined associations between the biomarkers and what patients ate, they found that body mass index alone did not fully account for the hormonal differences between patients and controls. Dietary composition, particularly the intake of fiber and fat, appeared to matter independently for hormone regulation in anorexia nervosa. This is a technically important observation because it implies that the quality and macronutrient profile of the diet, not merely the total energy delivered, may shape how the appetite-signaling system recovers. Fiber is well known to influence gut hormone secretion through fermentation by the gut microbiota, producing short-chain fatty acids that stimulate enteroendocrine L-cells, the very cells that produce GLP-1. Fat intake, meanwhile, influences both incretin release and the absorption kinetics of meals. The NORMA study’s microbiota focus makes this connection especially tantalizing, since the gut bacteria that ferment fiber are themselves altered in anorexia nervosa.

The clinical implications are considerable but deliberately framed as open questions by the authors. Nutritional treatment is a cornerstone of anorexia nervosa care, and weight restoration remains essential, yet the persistence of abnormal levels of glucagon, adiponectin, GIP, and GLP-1 after twelve weeks of intensive treatment suggests that weight gain alone may not fully repair the biological machinery of appetite. Whether these unresponsive hormones can be targeted through tailored nutritional strategies, such as manipulating fiber or fat intake, or through pharmacological therapies aimed at the gut–brain axis, remains to be investigated. The GLP-1 system is already a major drug target in obesity and diabetes, and understanding why it behaves anomalously in anorexia nervosa could open new therapeutic avenues for a disorder where restoring the drive to eat is the central clinical challenge.

The study’s design carries caveats that the authors acknowledge through its framing as exploratory. With 42 patients and 42 controls, the sample is modest, and the healthy controls were only measured once, limiting the ability to model within-person change in that group. Twelve weeks is a short window in the arc of recovery from an illness that often runs a chronic course, and the patients’ BMIs at the end of treatment were still below the healthy range, so it remains possible that some hormones would normalize with further weight restoration. Still, the trial was prospectively registered with ClinicalTrials.gov under identifier NCT06144905, and the longitudinal sampling within treatment gives the findings a temporal texture that cross-sectional studies cannot match. What emerges is a picture of anorexia nervosa as not only a psychological disorder of eating but a systemic endocrine condition, one in which the molecular conversation between gut and brain is disrupted at baseline, partially restored by refeeding, and in key respects strikingly resistant to change. For clinicians and researchers alike, the message is that the scale tells only part of the story, and that the hormones of hunger may hold the rest.

Subject of Research: Appetite-related biomarker changes during inpatient treatment of anorexia nervosa and their association with diet and body mass index

Article Title: Exploring appetite-related biomarkers in anorexia nervosa during treatment: associations with diet and comparison with healthy controls

Article References: Hovland, I. H., Otterdal, K. L., Bang, L., Vinje, H., Herfindal, A. M., Strømland, S. S., Aspholm, T. E., Arsenovic, D., Reistad, H. T., Dahl, J., Ones, M. L., Weider, S., Bulik, C. M., Rø, Ø., & Bøhn, S. K. (2026). Exploring appetite-related biomarkers in anorexia nervosa during treatment: associations with diet and comparison with healthy controls. Journal of Eating Disorders. https://doi.org/10.1186/s40337-026-01752-1

Image Credits: AI Generated

DOI: 10.1186/s40337-026-01752-1

Keywords: anorexia nervosa, appetite hormones, gut-brain axis, ghrelin, leptin, GLP-1, GIP, adiponectin, dietary fiber, nutritional rehabilitation, biomarkers, eating disorders

Adiponectin has long intrigued metabolic researchers because its concentrations move inversely with risk: the more of it circulating in the bloodstream, the lower the likelihood of type 2 diabetes, hypertension, and cardiovascular disease. Of particular interest is its high molecular weight form, the multimeric assembly of the protein that is considered the most biologically active variant and the strongest predictor of metabolic outcomes. Adults with histories of early life adversity — experiences such as abuse, neglect, household dysfunction, or chronic stress during childhood — tend to show elevated inflammatory markers and depressed adiponectin levels. Because inflammation sits at the hub of nearly every major cardiometabolic disease, this biochemical signature has been proposed as one pathway by which childhood hardship translates into adult illness decades later.

The stakes are especially high for females. Women face a comparatively greater lifetime risk of cardiometabolic disease, and puberty marks a period of pronounced metabolic change in which adipokine profiles begin to diverge by sex. If adversity’s physiological effects take root during adolescence, then identifying modifiable protective factors in teenage girls could pay enormous dividends across the lifespan. That reasoning drove the research team to ask a deceptively simple question: can emotional support — the perceived availability of people who listen, empathize, and provide reassurance — soften the impact of early adversity on adiponectin levels before adulthood begins?

To find out, the investigators enrolled 217 female adolescents between the ages of 13 and 17, with a mean age of 15.3 years. Early life adversity and emotional support were each measured with standardized, validated instruments, and serum samples were analyzed to quantify adiponectin concentrations. Crucially, the researchers designed their statistical models to disentangle the effects of adversity and support from potential confounders, adjusting for age, race and ethnicity, annual household income, and adiposity. The inclusion of adiposity as a covariate was particularly important because body fat mass strongly influences adiponectin secretion; without this control, any observed relationship could simply reflect differences in weight rather than the psychological environment.

The results revealed a clear moderation effect. Emotional support did not merely correlate with adiponectin levels in a general sense — it changed the very shape of the relationship between early adversity and this protective protein. Among participants who reported more severe early life adversity, those who also reported higher levels of emotional support exhibited higher adiponectin concentrations than peers whose support was average or lower. In statistical terms, the adversity-related suppression of adiponectin was attenuated, and in some cases reversed, in the presence of strong emotional support. The findings align with the classic buffering hypothesis, first articulated by Sheldon Cohen and Thomas Wills in the 1980s, which proposes that social support protects health most powerfully precisely when stress is highest.

The choice to focus on the emotional component of support rather than social support in general was deliberate and theoretically grounded. Decades of research in social psychology and health psychology have shown that functional dimensions of support differ in their physiological consequences. Emotional support — expressions of empathy, caring, and trust — appears to be a particularly salient form for women, whose stress responses and cardiovascular reactivity may benefit more from emotional closeness than from instrumental or informational assistance. Prior studies have linked perceived emotional support to lower ambulatory blood pressure, reduced cardiovascular reactivity to stress, and diminished subclinical atherosclerosis in middle-aged adults. The new study extends this line of evidence into adolescence, a developmental window rarely examined with molecular biomarkers.

Why would emotional support register in the blood as altered adiponectin? The authors point to the physiological pathways through which chronic childhood stress remodels metabolism. Early adversity is known to dysregulate the hypothalamic-pituitary-adrenal axis, sustain sympathetic nervous system arousal, and promote low-grade systemic inflammation. Adipose tissue is both a target and a source of this inflammatory milieu: inflammatory cytokines suppress adiponectin expression, while adiponectin itself counteracts inflammation, improves insulin sensitivity, and exerts anti-atherogenic effects on blood vessel walls. By dampening perceived stress and stress reactivity, emotional support may interrupt this cascade upstream, allowing adiponectin production to remain relatively preserved even in adolescents carrying substantial adversity burdens. The authors caution that the cross-sectional design cannot confirm causality — it remains possible that adversity influences both support networks and biology, or that the associations reflect other unmeasured factors — but the moderation pattern is consistent with a genuine protective mechanism.

The public health implications are considerable. Childhood adversity is strikingly common: surveillance data from the U.S. Centers for Disease Control and Prevention indicate that most American adults report at least one adverse childhood experience, and large cohort studies have linked such exposures to elevated risks of type 2 diabetes and cardiovascular disease in early adulthood. The American Heart Association has issued a formal scientific statement recognizing childhood and adolescent adversity as a cardiometabolic risk factor in its own right. Against this backdrop, the new findings suggest that interventions emphasizing emotional support — through family-based programs, peer support structures, school counseling, and therapeutic relationships — could function not merely as psychological comfort but as biological prevention, blunting the physiological embedding of adversity before it hardens into disease risk.

For clinicians and researchers alike, the study also raises a battery of productive questions. Would longitudinal designs confirm that emotionally supported adolescents maintain healthier adiponectin trajectories into adulthood? Would the same buffering appear in boys, whose support dynamics and metabolic physiology differ? Does the high molecular weight fraction of adiponectin respond to support-enhancing interventions in randomized trials? The research team notes that the larger study is ongoing, with additional participants to be enrolled, and that data are held in controlled-access storage because of their sensitive nature, with access available from the corresponding author upon reasonable request. The work was supported by National Institutes of Health grants, including R01MD010757, R01MH108155, R01DA040966, and R01DA058794.

What emerges most vividly from the analysis is a reframing of emotional support itself. Often dismissed as soft or intangible, support of this kind now appears to leave a measurable fingerprint in the blood of teenage girls — one associated with a protein that guards against diabetes, hypertension, and heart disease. For adolescents navigating the aftermath of early adversity, a reliable source of warmth and understanding may be one of the most affordable and scalable protective interventions available. The challenge for the field now is to convert that insight into programs, policies, and clinical practices that ensure high-risk youth actually receive it during the developmental years when it matters most.

Adiponectin’s biology helps explain why the high molecular weight fraction receives such close attention. The protein is produced by adipocytes and assembles into oligomers of varying size, and only the largest complexes appear capable of activating the intracellular signaling pathways responsible for insulin sensitization and vascular protection. Research in children and adolescents with obesity has identified high molecular weight adiponectin as a biomarker of hypertension risk at surprisingly young ages, and cross-sectional work in Danish schoolchildren has documented that total adiponectin and its oligomeric forms shift during puberty in sex-specific ways. These developmental patterns make adolescence a scientifically informative stage at which to examine how psychosocial experience might shape the adiponectin system.

The measurement choices in the study also merit note. Perceived emotional support was assessed with instruments derived from established social support inventories, which distinguish the emotional function of support from instrumental, informational, and other functions. This distinction matters because the physiological correlates of support appear to depend on which function is provided and on who receives it. Studies of ambulatory blood pressure, for example, have found that specific support dimensions predict cardiovascular outcomes differently depending on recipient characteristics, reinforcing the argument that a single global support score can obscure meaningful variation.

Socioeconomic context adds a further layer of interpretation. Household income was included as a covariate in the analyses, an appropriate decision given that adiponectin levels have been linked to socioeconomic status in large community samples such as the Jackson Heart Study, and that adversity and material hardship frequently co-occur. Similarly, race and ethnicity were modeled because serum adiponectin concentrations vary across ethnic groups independently of adiposity, as demonstrated in multi-ethnic urban cohorts. By accounting for these demographic and metabolic factors simultaneously, the moderation effect observed is less likely to be an artifact of group differences in body composition or social position.

The broader literature on childhood adversity and biomarkers supports the plausibility of the findings. Scoping reviews of adverse childhood experiences have catalogued alterations in inflammatory markers, endocrine parameters, and cellular aging processes among exposed individuals, while population-wide cohort studies following more than a million individuals have connected childhood adversity to elevated type 2 diabetes risk in early adulthood. Within this landscape, the identification of a modifiable psychosocial factor associated with preserved adiponectin in high-risk adolescent girls offers a concrete target. Whether interventions designed to strengthen emotional support can shift adiponectin trajectories prospectively remains an open question, but the present results provide a biologically grounded rationale for testing that proposition in future trials.

Subject of Research: How emotional support moderates the relationship between early life adversity and high molecular weight adiponectin levels in adolescent females

Article Title: Emotional Support Moderates Early Life Adversity’s Impact on High Molecular Weight Adiponectin in Adolescent Females

Article References: Daniels, K., Martinez, S., & Rao, U. (2026). Emotional Support Moderates Early Life Adversity’s Impact on High Molecular Weight Adiponectin in Adolescent Females. Journal of Child &amp; Adolescent Trauma. https://doi.org/10.1007/s40653-026-00977-1

Image Credits: AI Generated

DOI: 10.1007/s40653-026-00977-1

Keywords: early life adversity, emotional support, adiponectin, adolescent females, cardiometabolic disease, inflammation, social support, childhood trauma, metabolic health, puberty, biomarkers, stress buffering